Synthesis of dalbavancin
Scheme S1 Synthesis of dalbavancin TFA salt 4 from A40926.
General experimental
Routine analytical LCMS analysis was performed using a Shimadzu Prominence system utilising a SPD-M20A diode array UV-Vis detector, ELSD-LT II evaporative light scattering detector and LCMS-2020 mass spectrometer. Preparative HPLC was performed on an Agilent 1206 Infinity system, with monitoring at 210 nm. Final HPLC purity of dalbavancin 4 was assessed on an Agilent 1200 system, with monitoring at 210 nm. The following reverse phase columns were used throughout: column A: Agilent Zorbax Eclipse XDB-phenyl 
Amide (3)
Crude 1 (0.207 g) was dissolved in DMF (1.73 mL). PyBOP (0.0538 g) was added and the mixture agitated until homogeneous. The solution was cooled in an ice bath, and N,Ndimethyl-1,3-diaminopropane (0.029 mL) was added. The mixture was brought to room temperature. After 2 h, EtOAc (8 mL) was added and the resulting suspension was centrifuged. The supernatant was decanted, and the pellet was re-suspended in diethyl ether, and centrifuged once more. The supernatant was discarded, and the pellet freeze-dried from a minimum volume of 0.1% HOAc in CH 3 
clogP calculation
The property of clogP as previously described 1 was calculated by Pipeline Pilot (Accelrys, Dan Diego CA, USA).
Antibacterial activity determination
MICs of dalbavancin against MRSA ATCC 43300, S. pneumoniae (multi-drug-resistant) 
